I Peace, Inc.| Cell and Gene Therapy Manufacturing, cGMP iPSCs | CDMO

I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population. These lines cover more than 100 million people in the US. We have successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1. Two clonal lines are available for cell therapy developers and pharmaceutical companies as off-the-shelf products in both GMP and research-grade. https://lnkd.in/gxFPJ85n #CellTherapy #StemCellTherapy #RegenerativeMedicine

I Peace CEO Koji Tanabe appeared on a Japanese TV program "Sakurai, Ariyoshi The Night Party”, which was broadcast on Thursday, October 10. He explained about the Personal iPS cell banking service and its future possibilities. The program is available on the TVer until October 17. https://lnkd.in/gMB5BUeY

We're #hiring a new Quality Manager in Palo Alto, California. Apply today or share this post with your network.

I Peace CEO Koji Tanabe will appear on a Japanese TV program, “Sakurai・Ariyoshi THE Yakai “ (10 PM on October 10th Thursday, Japan time on the TBS network). He will discuss iPS cell personal services, as well as the future potential of iPS technology. It is a part of I Peace's efforts towards "the democratization of iPS cells" to make iPS cells available to everyone, by making it near and dear to the general public. Koji will discuss from the studio the personal iPS cell banking service and various applications of iPS cells, engaging in a lively conversation with guests and program MCs. Through this program, I Peace hopes that society as a whole will have a deeper understanding of iPS cell technology and that the development of the research and medical applications of iPS cells will be further accelerated.  https://lnkd.in/e5vTYmUZ

(From garage to the world) I Peace was born in 2015 in a small garage in Silicon Valley. To effectively utilize the precious funds and maximize the investment in research and development, we chose a garage with cheap rent to build our facility instead of renting spaces built for laboratories and offices, We did most of the interior work by ourselves, setting up walls and partitions to build laboratories and offices. In it, we installed analytical instruments such as FACS and fluorescence microscope, and R & D equipment such as incubator for cell culture. Our operation started by cultivating cells in this facility. We continued to improve our facility and today, the garage is equipped even with a clean room. For us, it is one of the joyous moments to see the guests surprised by the gap between the building’s exterior and the inside facility. Later we built a full-fledged cell manufacturing facility in Kyoto, Japan, licensed by Japan’s Ministry of Health, Labour and Welfare to manufacture clinical-grade cells. The facility is also registered as U.S. FDA Drug Establishment. Our Palo Alto quality control testing facility has been accredited as ISO 17025:2017 compliant. I Peace’s iPS cells and induced cell product, manufactured in world-class facilities under rigorous quality standards, are now shipped to pharmaceutical companies and cell therapy developers worldwide, making steady steps toward clinical trials.

Selected as One of the 100 Technologies Changing the World We are proud to announce that I Peace’s mass production system and products for personalized iPS cells have been selected as one of the 100 technologies changing the world and featured in a book. Moving forward, we will continue to leverage our technology for the mass production of personalized iPS cells to further democratize iPS cell therapy!

I Peace was featured in a business publication by Nikkei BP titled “Nikkei Technology Outlook 2025: 100 Technologies That Will Change the World” https://lnkd.in/gciKm3B9

We are excited to announce a new collaboration! "Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer" https://lnkd.in/gb66uptw

Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer - https://lnkd.in/ewK_iFg5 I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy. iCamuno will lead the trial, which will test the safety and efficacy of NK cells made from I Peace’s cGMP-compliant iPS cells using iCamuno’s NK cell differentiation technology. Natural killer (NK) cells are a critical component of the anti-cancer immune system, with natural abilities to recognize and destroy tumor cells. This trial leverages iCamuno’s abilities to create cGMP-grade iPS cell-derived NK cells with improved consistency and effector function. The initial phase will focus on ovarian cancer, with potential expansion to a broader range of diseases. “We are thrilled to reach this moment,” said Koji Tanabe, CEO and founder at I Peace, Inc.| Cell and Gene Therapy Manufacturing, cGMP iPSCs | CDMO. “Dosing the first patient in this trial using our iPS cell line is a significant milestone in our goal to develop innovative immunotherapies for cancer.” “This is an important milestone for iCamuno,” said Ethan Liu, Chairman and co-founder of iCamuno Biotherapeutics Pty Ltd. “Given their safety and efficacy in preclinical testing, we are hopeful that our iNK cells will be a valuable weapon in the battle against ovarian cancer.” #ipscells #stemcells #nkcells #advancedtherapies

Tune in to TV Tokyo's World Business Satellite on Wednesday, July 31, 2024, from 10:00 PM to 10:58 PM(JST). The collaboration among I Peace, KOSE Corporation, and Reju Inc., will be featured. Don’t miss it.  https://lnkd.in/dqrztQe